Skip to main content

Nasolabial Fold

0
Pipeline Programs
5
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Galderma
GaldermaTX - Dallas
4 programs
GP0045N/A1 trial
Restylane LidocaineN/A1 trial
Restylane Perlane LidocaineN/A1 trial
Sculptra AestheticN/A1 trial
Active Trials
NCT03300466Completed20Est. Apr 2019
NCT02918721Completed70Est. May 2017
NCT03174132Completed70Est. Jan 2018
+1 more trials
Huons
HuonsKorea - Seongnam
1 program
HARA FillerN/A1 trial
Active Trials
NCT04224649Unknown67Est. Jul 2020
Symbio Pharmaceuticals
1 program
SMI-01N/A1 trial
Active Trials
NCT04534660Completed21Est. Jun 2023
Sofregen Medical
Sofregen MedicalMA - Framingham
1 program
SMI-01N/A
JETEMA
JETEMAKorea - Gangwon
1 program
UNIVELO Sub-Q 2mLN/A1 trial
Active Trials
NCT07150273Completed65Est. Jul 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GaldermaSculptra Aesthetic
Symbio PharmaceuticalsSMI-01
HuonsHARA Filler
GaldermaGP0045
GaldermaRestylane Perlane Lidocaine
GaldermaRestylane Lidocaine
JETEMAUNIVELO Sub-Q 2mL

Clinical Trials (7)

Total enrollment: 323 patients across 7 trials

NCT04957446GaldermaSculptra Aesthetic

Histology Study of Biostimulatory Activity of Injectable Poly-L-Lactic Acid (Sculptra Aesthetic)

Start: Aug 2021Est. completion: Sep 202210 patients
N/AUnknown
NCT04534660Symbio PharmaceuticalsSMI-01

Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler

Start: Nov 2020Est. completion: Jun 202321 patients
N/ACompleted
NCT04224649HuonsHARA Filler

To Evaluate the Efficacy and Safety of Injection With HARA as Compared to Restylane® Lidocaine in Temporary Correction of Nasolabial Folds

Start: Apr 2019Est. completion: Jul 202067 patients
N/AUnknown
NCT03300466GaldermaGP0045

A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds

Start: Oct 2017Est. completion: Apr 201920 patients
N/ACompleted
NCT03174132GaldermaRestylane Perlane Lidocaine

Pain and Safety of Restylane Perlane With and Without Lidocaine for Correction of Moderate and Severe Nasolabial Folds

Start: Sep 2017Est. completion: Jan 201870 patients
N/ACompleted
NCT02918721GaldermaRestylane Lidocaine

Pain and Safety of Restylane With and Without Lidocaine for Correction of Moderate and Severe Nasolabial Folds

Start: Feb 2017Est. completion: May 201770 patients
N/ACompleted
NCT07150273JETEMAUNIVELO Sub-Q 2mL

A Clinical Study to Evaluate the Efficacy and Safety of the Injection With UNIVELO Sub-Q, as Compared to Restylane® Sub-Q, in the Temporary Correction of the Nasolabial Fold

Start: Feb 2016Est. completion: Jul 201765 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.